| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
New tests launched in February
New Tests
In February 2021, Mayo Clinic Laboratories announced three new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
The new tests that launched in February 2021 by Mayo Clinic Laboratories:
COVSQ | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Spike Antibody, Semi-Quantitative, Serum
This test is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating prior infection and/or vaccination.
THSIF | Thrombospondin Type 1 Domain Containing 7A (THSD7A), Immunofluorescence
This test is intended for use as an aid in the diagnosis of thrombospondin type 1 domain-containing 7A (THSD7A)-associated membranous nephropathy
EMAIG | Endomysial Antibodies (IgG), Serum
This test is intended for use as an aid in the diagnosis of dermatitis herpetiformis and celiac disease.
In addition to these tests, the department also announced several test changes. Click the links below to view test changes announced by Mayo Clinic Laboratories:
